These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 11928278

  • 1. [The ACE inhibitor, captopril, in the light of new clinical studies].
    Simko F, Simková M, Kovacs L.
    Ceska Slov Farm; 2002 Mar; 51(2):63-7. PubMed ID: 11928278
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer M.
    J Am Coll Cardiol; 2006 Feb 21; 47(4):726-33. PubMed ID: 16487836
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 5. [ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome].
    Milicić D.
    Acta Med Croatica; 2004 Jul 15; 58(2):129-34. PubMed ID: 15208798
    [Abstract] [Full Text] [Related]

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep 15; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 7. Current recommendations for the treatment of hypertension: are they still valid?
    Moser M.
    J Hypertens Suppl; 2002 Feb 15; 20(1):S3-10. PubMed ID: 11996197
    [Abstract] [Full Text] [Related]

  • 8. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA, VALIANT Investigators.
    Circulation; 2005 Nov 29; 112(22):3391-9. PubMed ID: 16301343
    [Abstract] [Full Text] [Related]

  • 9. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA.
    Circulation; 2005 Jun 28; 111(25):3411-9. PubMed ID: 15967846
    [Abstract] [Full Text] [Related]

  • 10. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 28; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 11. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 28; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 12. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, VALIANT Investigators.
    Am Heart J; 2005 Aug 28; 150(2):323-9. PubMed ID: 16086938
    [Abstract] [Full Text] [Related]

  • 13. Clinical studies on the therapy of heart failure using ACE-inhibitors and AT1-receptor blockers--does combination treatment make sense?
    Hennig L.
    Clin Nephrol; 2002 Jul 28; 58 Suppl 1():S7-11. PubMed ID: 12227730
    [Abstract] [Full Text] [Related]

  • 14. [Angiotensin-converting enzyme inhibitors :from vasoactive drugs to cardiovascular prevention tools].
    Modesti PA, Vanni S, Gensini GF.
    Ital Heart J Suppl; 2003 Aug 28; 4(8):623-34. PubMed ID: 14655458
    [Abstract] [Full Text] [Related]

  • 15. Early and chronic captopril or Losartan therapy reduces infarct size and avoids congestive heart failure after myocardial infarction in rats.
    Martínez LA, Villalobos-Molina R.
    Arch Med Res; 2003 Aug 28; 34(5):357-61. PubMed ID: 14602500
    [Abstract] [Full Text] [Related]

  • 16. [Efficiancy Angiotensin -converting enzyme inhibitors for the clinical practice].
    Abuladze GV, Nebieridze MI, Narsiia EV, Erkomaishvili IG, Pipiia NG.
    Georgian Med News; 2011 Jun 28; (195):37-40. PubMed ID: 21778538
    [Abstract] [Full Text] [Related]

  • 17. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
    Aguilar D, Solomon SD, Køber L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O'Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA.
    Circulation; 2004 Sep 21; 110(12):1572-8. PubMed ID: 15364810
    [Abstract] [Full Text] [Related]

  • 18. [ACE inhibitor or AT1 antagonist. Is there a differential therapy?].
    Unger T, Rangoonwala B, Rosenthal J.
    MMW Fortschr Med; 2002 Jun 13; 144(24):36-8. PubMed ID: 12134723
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H.
    Ther Apher Dial; 2004 Aug 13; 8(4):320-7. PubMed ID: 15274684
    [Abstract] [Full Text] [Related]

  • 20. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr 13; 15(82):46-9. PubMed ID: 16604728
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.